{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:52:35Z","timestamp":1790949155294,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T00:00:00Z","timestamp":1485216000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00520-017-3583-1","type":"journal-article","created":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T06:49:59Z","timestamp":1485240599000},"page":"1845-1851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States"],"prefix":"10.1007","volume":"25","author":[{"given":"Yi","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debajyoti","family":"Bhowmik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"Kachru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini K.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,24]]},"reference":[{"issue":"20 Pt 2","key":"3583_CR1","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical cancer research: an official journal of the American Association for Cancer Research 12(20 Pt 2):6243s\u20136249s. doi:\n10.1158\/1078-0432.CCR-06-0931","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"Suppl 4","key":"3583_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","volume":"9","author":"RE Coleman","year":"2004","unstructured":"Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9(Suppl 4):14\u201327. doi:\n10.1634\/theoncologist.9-90004-14","journal-title":"Oncologist"},{"issue":"1","key":"3583_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","volume":"184","author":"M Norgaard","year":"2010","unstructured":"Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184(1):162\u2013167. doi:\n10.1016\/j.juro.2010.03.034","journal-title":"J Urol"},{"issue":"2","key":"3583_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","volume":"129","author":"M Yong","year":"2011","unstructured":"Yong M, Jensen AO, Jacobsen JB, Norgaard M, Fryzek JP, Sorensen HT (2011) Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat 129(2):495\u2013503. doi:\n10.1007\/s10549-011-1475-5","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"3583_CR5","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082\u20131090","journal-title":"Cancer"},{"issue":"1","key":"3583_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.urolonc.2005.06.020","volume":"24","author":"F Saad","year":"2006","unstructured":"Saad F, McKiernan J, Eastham J (2006) Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Urol Oncol 24(1):4\u201312. doi:\n10.1016\/j.urolonc.2005.06.020","journal-title":"Urol Oncol"},{"issue":"12","key":"3583_CR7","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1007\/s00520-013-1887-3","volume":"21","author":"G Oster","year":"2013","unstructured":"Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, Richhariya A, Dodge T, Wolff GG, Balakumaran A, Edelsberg J (2013) Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 21(12):3279\u20133286. doi:\n10.1007\/s00520-013-1887-3","journal-title":"Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer"},{"issue":"11","key":"3583_CR8","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1002\/cncr.22678","volume":"109","author":"KL Schulman","year":"2007","unstructured":"Schulman KL, Kohles J (2007) Economic burden of metastatic bone disease in the U.S. Cancer 109(11):2334\u20132342. doi:\n10.1002\/cncr.22678","journal-title":"Cancer"},{"issue":"2","key":"3583_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","volume":"42","author":"KP Weinfurt","year":"2004","unstructured":"Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA (2004) Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 42(2):164\u2013175. doi:\n10.1097\/01.mlr.0000108746.69256.45","journal-title":"Med Care"},{"issue":"Suppl 3","key":"3583_CR10","doi-asserted-by":"publisher","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","volume":"25","author":"R Coleman","year":"2014","unstructured":"Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J, Group EGW (2014) Bone health in cancer patients: ESMO clinical practice guidelines. Annals of oncology: official journal of the European Society for Medical Oncology \/ ESMO 25(Suppl 3):iii124\u2013iii137. doi:\n10.1093\/annonc\/mdu103","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology \/ ESMO"},{"issue":"Suppl 3","key":"3583_CR11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2013.0215","volume":"11","author":"JR Gralow","year":"2013","unstructured":"Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R, Litsas G, McKay R, Podoloff DA, Srinivas S, Van Poznak CH (2013) NCCN task force report: bone health in cancer care. Journal of the National Comprehensive Cancer Network: JNCCN 11(Suppl 3):S1\u201350 quiz S51","journal-title":"Journal of the National Comprehensive Cancer Network: JNCCN"},{"key":"3583_CR12","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines. \nhttp:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site\n\n. Accessed 23 Feb 2016"},{"key":"3583_CR13","unstructured":"Aredia (pamidronate disodium) prescribing information. \nhttp:\/\/www.novartis.com.au\/PI_PDF\/apd.pdf\n\n. Accessed 31 Jan 2016"},{"key":"3583_CR14","unstructured":"XGEVA (denosumab) prescribing information. \nhttp:\/\/www.xgeva.com\/hcp\/xgeva-dosing-and-administration.html\n\n. Accessed 31 Jan 2016"},{"issue":"3","key":"3583_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1586\/era.11.204","volume":"12","author":"JJ Body","year":"2012","unstructured":"Body JJ (2012) Denosumab for the management of bone disease in patients with solid tumors. Expert Rev Anticancer Ther 12(3):307\u2013322. doi:\n10.1586\/era.11.204","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"3583_CR16","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.3747\/co.22.2380","volume":"22","author":"J Arellano","year":"2015","unstructured":"Arellano J, Gonzalez JM, Qian Y, Habib M, Mohamed AF, Gatta F, Hauber AB, Posner J, Califaretti N, Chow E (2015) Physician preferences for bone metastasis drug therapy in Canada. Curr Oncol 22(5):e342\u2013e348. doi:\n10.3747\/co.22.2380","journal-title":"Curr Oncol"},{"issue":"15","key":"3583_CR17","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1002\/pros.22865","volume":"74","author":"AB Hauber","year":"2014","unstructured":"Hauber AB, Arellano J, Qian Y, Gonzalez JM, Posner JD, Mohamed AF, Gatta F, Tombal B, Body JJ (2014) Patient preferences for treatments to delay bone metastases. Prostate 74(15):1488\u20131497. doi:\n10.1002\/pros.22865","journal-title":"Prostate"},{"issue":"10","key":"3583_CR18","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1007\/s00520-014-2251-y","volume":"22","author":"RK Hernandez","year":"2014","unstructured":"Hernandez RK, Quigley J, Pirolli M, Quach D, Chen KS, Arellano J, Liede A (2014) Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 22(10):2697\u20132705. doi:\n10.1007\/s00520-014-2251-y","journal-title":"Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer"},{"issue":"5","key":"3583_CR19","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00520-013-2094-y","volume":"22","author":"G Oster","year":"2014","unstructured":"Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, Richhariya A, Dodge T, Wolff GG, Balakumaran A, Edelsberg J (2014) Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 22(5):1363\u20131373. doi:\n10.1007\/s00520-013-2094-y","journal-title":"Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer"},{"issue":"1","key":"3583_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00520-013-1951-z","volume":"22","author":"M Hagiwara","year":"2014","unstructured":"Hagiwara M, Delea TE, Cong Z, Chung K (2014) Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 22(1):103\u2013113. doi:\n10.1007\/s00520-013-1951-z","journal-title":"Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer"},{"key":"3583_CR21","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2147\/CLEP.S85496","volume":"7","author":"RK Hernandez","year":"2015","unstructured":"Hernandez RK, Adhia A, Wade SW, O'Connor E, Arellano J, Francis K, Alvrtsyan H, Million RP, Liede A (2015) Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States. Clinical epidemiology 7:335\u2013345. doi:\n10.2147\/CLEP.S85496","journal-title":"Clinical epidemiology"},{"key":"3583_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2147\/CLEP.S92209","volume":"7","author":"A Liede","year":"2015","unstructured":"Liede A, Hernandez RK, Roth M, Calkins G, Larrabee K, Nicacio L (2015) Validation of international classification of diseases coding for bone metastases in electronic health records using technology-enabled abstraction. Clinical epidemiology 7:441\u2013448. doi:\n10.2147\/CLEP.S92209","journal-title":"Clinical epidemiology"},{"issue":"1","key":"3583_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jval.2014.10.004","volume":"18","author":"J Arellano","year":"2015","unstructured":"Arellano J, Hauber AB, Mohamed AF, Gonzalez JM, Collins H, Hechmati G, Gatta F, Qian Y (2015) Physicians' preferences for bone metastases drug therapy in the United States. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research 18(1):78\u201383. doi:\n10.1016\/j.jval.2014.10.004","journal-title":"Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research"},{"issue":"1","key":"3583_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00520-014-2309-x","volume":"23","author":"G Hechmati","year":"2015","unstructured":"Hechmati G, Hauber AB, Arellano J, Mohamed AF, Qian Y, Gatta F, Haynes I, Bahl A, von Moos R, Body JJ (2015) Patients\u2019 preferences for bone metastases treatments in France, Germany and the United Kingdom. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 23(1):21\u201328. doi:\n10.1007\/s00520-014-2309-x","journal-title":"Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer"},{"issue":"Suppl 1","key":"3583_CR25","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1053\/j.seminoncol.2010.06.006","volume":"37","author":"JE Mortimer","year":"2010","unstructured":"Mortimer JE, Pal SK (2010) Safety considerations for use of bone-targeted agents in patients with cancer. Semin Oncol 37(Suppl 1):S66\u2013S72. doi:\n10.1053\/j.seminoncol.2010.06.006","journal-title":"Semin Oncol"},{"issue":"1","key":"3583_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3111\/13696998.2011.632044","volume":"15","author":"HJ Henk","year":"2012","unstructured":"Henk HJ, Kaura S (2012) Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan. J Med Econ 15(1):175\u2013184. doi:\n10.3111\/13696998.2011.632044","journal-title":"J Med Econ"},{"issue":"1","key":"3583_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1185\/03007995.2010.535511","volume":"27","author":"HT Hatoum","year":"2011","unstructured":"Hatoum HT, Lin SJ, Guo A, Lipton A, Smith MR (2011) Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Curr Med Res Opin 27(1):55\u201362. doi:\n10.1185\/03007995.2010.535511","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"3583_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clbc.2011.03.015","volume":"11","author":"HT Hatoum","year":"2011","unstructured":"Hatoum HT, Lin SJ, Smith MR, Guo A, Lipton A (2011) Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis. Clinical breast cancer 11(3):177\u2013183. doi:\n10.1016\/j.clbc.2011.03.015","journal-title":"Clinical breast cancer"},{"issue":"6","key":"3583_CR29","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/cncr.23775","volume":"113","author":"HT Hatoum","year":"2008","unstructured":"Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A (2008) Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 113(6):1438\u20131445. doi:\n10.1002\/cncr.23775","journal-title":"Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3583-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-017-3583-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3583-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T05:05:09Z","timestamp":1493010309000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-017-3583-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,24]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["3583"],"URL":"https:\/\/doi.org\/10.1007\/s00520-017-3583-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,24]]}}}